“The biotech DBV Technologies will consolidate its securities listed on the American Nasdaq, what is the interest?”

“The biotech DBV Technologies will consolidate its securities listed on the American Nasdaq, what is the interest?”
“The biotech DBV Technologies will consolidate its securities listed on the American Nasdaq, what is the interest?”

Nasdaq headquarters in New York, in Times Square.
650166489/Anne Czichos – stock.adobe.com

Business life, market functioning, stock market law, etc. The editorial staff of Le Figaro Patrimoine et Bourse will answer your questions and provide you with their expertise.

In 2014, the French biotech listed in also listed on Wall Street, on the Nasdaq, using a mirror security: an ADS, for “American depositary share”. The French share was then trading at around €35 ​​and the parity chosen was one French security for each American ADS. But today, DBV Technologies shares fell to around €0.65.

Hunting penny stocks on the Nasdaq

Problem, Nasdaq has just tightened the rules applicable to volatiles penny stocks which are several hundred: basically, securities that trade under $1 for more than 360 sessions will be delisted. In response to this new rule, DBV has decided that from November 29, each of its ADSs will no longer reflect one, but five French shares. What in fact will correspond to a grouping of ADSs whose value will mechanically return above $1.

Belgium

-

-

PREV we know how many points Vitinha collected
NEXT BP abandons oil reduction target